Initial Treatment Choice in Depression

Eric Edgell, Timothy Hylan, JoLaine Draugalis and Stephen Coons

PharmacoEconomics, 2000, vol. 17, issue 4, 382 pages

Abstract: Objective: The purpose of this study was to examine the economic outcomes associated with initial treatment choice following a diagnosis of depression. Methods: Insurance claims data were used to classify patients into one of 4 treatment cohorts: no therapy, psychotherapy, drug therapy and combination therapy. Potential sample selection bias was accounted for by using a 2-stage econometric estimation procedure where initial treatment choice was estimated using a multinomial logistic regression model in the first stage, and total and mental healthcare costs were estimated in ordinary least squares regression models in the second stage. Log predicted costs from the second stage were compared to determine the relative costs associated with each cohort. Results: Significant differences (p > 0.008) in total costs were found between the combination therapy (log predicted cost=9.526) and psychotherapy cohorts (log predicted cost=8.120) in the analysis that included all observations (n=9110). In the analysis that included patients who initiated therapy with a non-mental health provider (n=2673), the drug therapy cohort (log predicted cost=8.238) was found to be significantly more costly as compared to the no therapy cohort (log predicted cost=7.788). Conclusions: These results indicate that after controlling for both observed and unobserved factors, total healthcare costs may be higher in patients who initiate therapy with drug therapy and combination therapy as opposed to no therapy or psychotherapy. In addition, the finding that patients initially receiving psychotherapy alone tend to have higher mental healthcare costs but lower total healthcare costs than other patients may indicate that psychotherapy has an impact on comorbid illness and may subsequently reduce total healthcare costs. Copyright Adis International Limited 2000

Date: 2000
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.2165/00019053-200017040-00007 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:17:y:2000:i:4:p:371-382

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.2165/00019053-200017040-00007

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().